Rethinking HER2 Status in Breast Cancer
In this enlightening Sagely Health webinar, join Jeremy, CTO at Sagely Health, and Dr. Jason Sager, MD, founder of Sagely Health, as they delve into the crucial topic of HER2-low breast cancer. This discussion aims to shed light on a lesser-known but significant area of breast cancer research that impacts many patients.
Dr. Sager provides a comprehensive overview of breast cancer fundamentals, emphasizing the role of receptors like ER, PR, and HER2 in diagnosis and treatment. The webinar highlights the groundbreaking discovery of HER2-low breast cancer, explaining its diagnosis, implications for patient care, and the evolving landscape of targeted therapies.Discover the nuances of HER2-low classification, learn about the latest advancements in treatment options, and understand the importance of proactive patient inquiry in managing this condition.
Dr. Sager also discusses the broader implications of HER2 in cancers beyond breast cancer, emphasizing the importance of genetic testing and personalized treatment approaches.Whether you are a patient, caregiver, or healthcare professional, this webinar offers valuable insights into the dynamic field of breast cancer treatment and research, particularly focusing on the emerging category of HER2-low breast cancer. Stay informed and explore potential treatment avenues, including clinical trials, for this specific breast cancer subtype.
Most patients are handed a treatment plan and told to begin. But what if there are better options—or steps being missed?
This free 5-day email series helps you understand the hidden opportunities that could shape your care. It covers what many patients wish they had known sooner—before key decisions were made.
You’ll get insights on:
Each short email builds on the last, helping you feel more informed and in control—right when decisions matter most.
Join hundreds of patients gaining clarity and confidence—in just 5 short emails.
